Evidence map›Paper›PMID 38093213›Full record

ArticleBMC gastroenterology2023

Identifying inflammatory bowel disease patients at risk of metabolic dysfunction-associated fatty liver disease: usefulness of non-invasive steatosis predictive scores.

Tiago Lima Capela, Vítor Macedo Silva, Marta Freitas, Cátia Arieira, Tiago Cúrdia Gonçalves, Francisca Dias de Castro, Joana Magalhães, José Cotter

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC gastroenterology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06328452 (Risk Factors and Impact of Metabolic Dysfunction -Associated Steatotic Liver Disease in Patients With Inflammatory Bowel Disease), which is not on this map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.3field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06328452 unknown statusnot on this mapstarted 2024, after this paper: background citation

Risk Factors and Impact of Metabolic Dysfunction -Associated Steatotic Liver Disease in Patients With Inflammatory Bowel Disease

TypeobservationalSponsorAssiut UniversityRan2024 to 2025Enrolled120ConditionsMetabolic Dysfunction-associated Steatotic Liver DiseaseArmsFibroScan
3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Enduring Dilemmas in Gastroenterology.Diagnostics (Basel, Switzerland) · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Tiago Lima CapelaHospital Senhora da Oliveira, Gastroenterology Department, Guimarães, Portugal. tiagolimacapela@gmail.com.ORCID http://orcid.org/0000-0002-8010-4410
Vítor Macedo SilvaHospital Senhora da Oliveira, Gastroenterology Department, Guimarães, Portugal.ORCID http://orcid.org/0000-0001-8001-9067
Marta FreitasHospital Senhora da Oliveira, Gastroenterology Department, Guimarães, Portugal.ORCID http://orcid.org/0000-0002-1782-6373
Cátia ArieiraHospital Senhora da Oliveira, Gastroenterology Department, Guimarães, Portugal.
Tiago Cúrdia GonçalvesHospital Senhora da Oliveira, Gastroenterology Department, Guimarães, Portugal.ORCID http://orcid.org/0000-0001-5540-6452
Francisca Dias de CastroHospital Senhora da Oliveira, Gastroenterology Department, Guimarães, Portugal.
Joana MagalhãesHospital Senhora da Oliveira, Gastroenterology Department, Guimarães, Portugal.
José CotterHospital Senhora da Oliveira, Gastroenterology Department, Guimarães, Portugal.ORCID http://orcid.org/0000-0002-2921-0648
Hospital da Senhora da Oliveira Guimarães · PT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundInflammatory bowel disease (IBD) patients have a higher risk of metabolic dysfunction-associated fatty liver disease (MAFLD) compared with the general population. However, it is not known whether available non-invasive hepatic steatosis scores are useful in predicting MAFLD in IBD patients. We aimed to analyze the performances of MAFLD screening score (MAFLD-S), Fatty Liver Index (FLI), Hepatic Steatosis Index (HSI) and Clinical Prediction Tool for NAFLD in Crohn's Disease (CPN-CD), in identifying MAFLD in IBD patients.

methodsA cross-sectional study was carried out including consecutive adult IBD outpatients submitted to transient elastography (TE). MAFLD criteria were assessed, and hepatic steatosis (HS) was defined by a controlled attenuation parameter (CAP) >248 dB/m using TE. MAFLD-S, FLI, HSI, and CPN-CD were calculated and their accuracy for the prediction of MAFLD was evaluated through their areas under the receiver-operating characteristic (AUROC) curves.

resultsOf 168 patients, body mass index ≥25, type 2 diabetes mellitus, dyslipidemia and arterial hypertension were present in 76 (45.2%), 10 (6.0%), 53 (31.5%), 20 (11.9%), respectively. HS was identified in 77 (45.8%) patients, of which 65 (84.4%) fulfilled MAFLD criteria. MAFLD-S (AUROC, 0.929 [95% CI, 0.888-0.971]) had outstanding and FLI (AUROC, 0.882 [95% CI, 0.830-0.934]), HSI (AUROC, 0.803 [95% CI, 0.736-0.871]), and CPN-CD (AUROC, 0.822 [95% CI, 0.753-0.890) had excellent discrimination in predicting MAFLD.

conclusionsMAFLD-S, FLI, HSI and CPN-CD scores can accurately identify MAFLD in IBD patients, allowing the selection of those in whom hepatic steatosis and metabolic risk factors assessment may be particularly beneficial.

Indexed as

Diabetes Mellitus, Type 2Inflammatory Bowel DiseasesNon-alcoholic Fatty Liver DiseaseAdultCross-Sectional StudiesHumansInflammatory bowel diseaseMetabolic dysfunction-associated fatty liver diseaseNonalcoholic fatty liver diseaseNon-invasive scores

Identifiers

PMID38093213
PMCPMC10720099
OpenAlexW4389673055

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.